Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials
Authors:
- Rajesh PahwaRPRajesh Pahwa
- Jason AldredJAJason Aldred
- Michael J. SoileauMSMichael J. Soileau
- David G. StandaertDSDavid G. Standaert
- Victor S. C. FungVFVictor S. C. Fung
- Thomas KimberTKThomas Kimber
- Irene A. MalatyIMIrene A. Malaty
- Diego Santos-GarcíaDSDiego Santos-García
- Camille CarrollCCCamille Carroll
- Tove HenriksenTHTove Henriksen
- Connie H. YanCYConnie H. Yan
Open Access
- 4 October 2025
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (6) , 2491-2506
Abstract
Introduction People with advanced Parkinson’s disease (aPD) frequently experience unpredictable “Off” time and debilitating motor fluctuations. Foslevodopa/foscarbidopa (LDp/CDp), a levodopa/carbidopa (LD/CD) prodrug, is delivered as a 24-h continuous subcutaneous infusion. This post hoc analysis evaluated the efficacy of LDp/CDp in achieving consistent motor symptom control and stable motor states in people with aPD. Methods Diaries of people with aPD treated with LDp/CDp participating in a 12-week, phase 3, randomized controlled trial (RCT) were evaluated versus oral LD/CD, and in a 52-week open-label, single-arm trial (OLT) with LDp/CDp alone. Motor symptom control was assessed by frequency (30-min intervals) and duration (4-h blocks) of motor states (good “On” time [without dyskinesia or troublesome dyskinesia] or “Off” time) over a 16-h waking day. Motor state stability was evaluated by changes in daily motor fluctuations and extreme fluctuations (defined as transition from “Off” to “On” with troublesome dyskinesia, or vice versa). Outcomes were analyzed using adjusted regression models. Results Analysis included 47 (RCT) and 55 (OLT) people with aPD on LDp/CDp. In the RCT, LDp/CDp had an approximately 1-h gain in good “On” time in the mornings versus a quarter-hour gain for those on LD/CD (P = 0.001), with > 80% of participants on LDp/CDp waking up in good “On.” At week 12, fewer motor fluctuations/day occurred with LDp/CDp versus LD/CD (3.2 vs 5.3; nominal P = 0.001), and twice as many participants on LDp/CDp had ≤ 3 fluctuations/day (53.2% vs 25.8%). In the OLT, the results seen at 12 weeks were sustained through week 52, with fewer mean fluctuations/day (3.1) than baseline (7.4) and more participants reporting ≤ 3 fluctuations/day at 52 weeks (66.6%) versus baseline (12.9%). Conclusion LDp/CDp provided consistent motor symptom control throughout the day, enhanced motor state stability, and reduced motor fluctuation, highlighting LDp/CDp’s potential to significantly improve the management of unpredictable motor states and overall quality of life for people with aPD. Trial information Clinicaltrials.gov ID: NCT04380142, NCT03781167.Keywords
Funding Information
- AbbVie
This publication has 21 references indexed in Scilit:
- Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approachCurrent Medical Research and Opinion, 2018
- Delayed Gastric Emptying in Advanced Parkinson DiseaseClinical Nuclear Medicine, 2017
- Consensus on the Definition of Advanced Parkinson’s Disease: A Neurologists-Based Delphi Study (CEPA Study)Parkinson's Disease, 2017
- Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's DiseaseMovement Disorders Clinical Practice, 2016
- Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis.2015
- Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy studyThe Lancet Neurology, 2014
- Treatment Options in the Modern Management of Parkinson DiseaseArchives of Neurology, 2007
- Delayed early morning turn "ON" in response to a single dose of levodopa in advanced Parkinson's disease: pharmacokinetics should be consideredJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Parkinson's disease home diary: Further validation and implications for clinical trialsMovement Disorders, 2004
- A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and DyskinesiaClinical Neuropharmacology, 2000